Fig. 4From: Nanobodies: a tool to open new horizons in diagnosis and treatment of prostate cancerNumerous VHH have been designed and manufactured against prostate cancer antigens, most of which are against PSA (prostate-specific antigen) or PSMA (prostate-specific membrane antigen) antigens. By attaching these nanobodies to reporter molecules, prostate cancer can be detected by ELISA, flow cytometry, immunohistochemistry, etc.Back to article page